Verily Life Sciences

Verily Life Sciences
Name	Verily Life Sciences
Type	Subsidiary
Industry	Healthcare, Life Sciences, Biotechnology
Founded	2015
Founder	Andrew Conrad
Hq location	South San Francisco, California, U.S.
Parent	Alphabet Inc.
Key people	Stephen Gillett (CEO)

Verily Life Sciences. It is a research and development organization focused on applying technology to healthcare and the life sciences. Founded as a subsidiary of Alphabet Inc., the company aims to leverage data-driven approaches to understand health and manage disease. Its work spans from advanced sensing and analytics to the development of novel interventions and medical devices.

History

Verily was established in 2015 as a rebranding and expansion of Google X's life sciences division, which had been operating since 2013 under the leadership of founder Andrew Conrad. The creation of Verily coincided with the formation of Alphabet Inc. as the new parent holding company, placing it alongside other "Other Bets" like Waymo and DeepMind. Early initiatives were rooted in ambitious, long-term projects such as the Baseline Study, which sought to map human health. In 2017, the company raised over $800 million in funding from external investors including Temasek Holdings and Silver Lake, signaling a shift toward more collaborative and commercially oriented ventures. Subsequent years saw Verily establish its headquarters in South San Francisco, California and expand its operational footprint through numerous strategic partnerships and acquisitions.

Research and development

The organization's research philosophy centers on integrating hardware, software, data science, and clinical medicine. Core R&D areas include ophthalmology, oncology, cardiology, endocrinology, and neuroscience. A significant focus is the development of miniaturized sensors and wearable technology for continuous health monitoring, such as the Study Watch used in clinical research. Verily also invests heavily in artificial intelligence and machine learning algorithms to derive insights from complex multimodal datasets, including genomic, proteomic, and environmental information. Its interdisciplinary teams, comprising experts from fields like bioengineering and computational biology, work on platforms designed to detect diseases earlier and enable more precise interventions.

Products and projects

Notable projects include the Smart Lens initiative, a collaboration initially with Novartis and later with Alcon, aimed at developing a contact lens to measure glucose in tears. The Triton platform is a suite of tools for clinical research and decentralized trials. In diagnostics, Verily has developed the Galileo platform for genetic risk assessment and the Verily Immune Profiler for deep immunophenotyping. The Project Baseline health study, conducted with partners like the Duke University School of Medicine and Stanford Medicine, is a longitudinal effort to collect comprehensive health data. Other ventures include Onduo, a virtual diabetes management platform developed with Sanofi, and surgical robotics projects like the Verb Surgical joint venture with Johnson & Johnson.

Partnerships and collaborations

Collaboration is a cornerstone of Verily's strategy, involving alliances with pharmaceutical companies, academic institutions, and healthcare systems. Major pharmaceutical partners include Pfizer, Sanofi, and Novartis for projects in rheumatoid arthritis, diabetes, and ophthalmic diseases. Academic research is conducted with entities like the Broad Institute and Harvard Medical School. The company has also formed significant alliances with healthcare providers, including Duke Health and the American Heart Association. In 2020, Verily partnered with the State of California and federal agencies to help operationalize COVID-19 testing sites and screening tools, working alongside the California Governor's Office of Emergency Services and the U.S. Department of Health and Human Services.

Leadership and organization

The company is led by CEO Stephen Gillett, who succeeded Andrew Conrad in 2018. Key executives have included Chief Medical Officer Amy Abernethy, formerly of the U.S. Food and Drug Administration, and Chief Scientific Officer Vivian Lee. Verily operates as an independent subsidiary under Alphabet Inc., with its own board of directors and significant autonomy in operations and fundraising. The organizational structure is designed to foster agile, project-based teams that can rapidly prototype and test new ideas. It maintains a workforce blending talent from technology sectors, clinical research, and the biomedical industry, with major operational hubs in the San Francisco Bay Area and Cambridge, Massachusetts.

Impact and reception

Verily has generated significant attention for its ambitious attempts to disrupt traditional biotechnology and healthcare models. Its data-centric approach to the Baseline Study has been praised for its scale and potential to redefine preventive medicine. However, some projects, like the Smart Lens, have faced public setbacks and technical challenges, leading to scrutiny from the medical and investment communities. The company's work during the COVID-19 pandemic in the United States was both lauded for its rapid deployment and critiqued for initial operational hurdles. Overall, Verily is viewed as a influential player in the digital health landscape, though its long-term success in translating technological innovation into widespread clinical utility remains a subject of ongoing observation.

Category:Biotechnology companies of the United States Category:Alphabet Inc. subsidiaries Category:Companies based in San Mateo County, California